A Phase 1/2 interventional study of BMS-986277 and Nivolumab in Cancer, sponsored by Bristol-Myers Squibb. Terminated at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-19.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to investigate experimental medication BMS-986277 given alone and in combination with Nivolumab in patients with epithelial cancers.
10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.
This study's enrollment of 10 is below the median of 60 across 7,714 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMS-986277 administered alone
Biological: BMS-986277
BMS-986277 administered in combination with Nivolumab
Biological: BMS-986277 · Biological: Nivolumab
BMS-986277 monotherapy with option for subsequent Nivolumab therapy
Biological: BMS-986277 · Biological: Nivolumab
Specified dose on specified days
Specified dose on specified days
Also known as: Opdivo, BMS-963558
Number of Participants With an Adverse Event (AE)
Number of participants who experienced an AE during the course of the study.
Time frame: from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)
Number of Participants With a Serious Adverse Event (SAE)
Number of participants who experienced a SAE during the course of the study.
Time frame: from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)
Number of Participants With an Adverse Event (AE) Meeting Protocol-defined Dose Limiting Toxicity (DLT) Criteria
Number of participants who experienced an AE meeting protocol-defined DLT criteria during the course of the study.
Time frame: from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)
Number of Participants With an Adverse Event (AE) Leading to Discontinuation
Number of participants who experienced an AE leading to discontinuation during the course of the study.
Time frame: from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)
Number of Participants With an Adverse Event (AE) Leading to Death
Number of participants who experienced an AE leading to death during the course of the study.
Time frame: from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)
Number of Participants With a Clinical Laboratory Test Abnormality
Number of participants who experienced a clinical laboratory test abnormality during the course of the study.
Time frame: from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)
Number of Participants With a Vital Sign Abnormality or Other Safety Biomarkers
Number of participants who experienced a vital sign abnormality or other safety biomarkers during the course of the study.
Time frame: from first dose to 60 days post last dose, assessed up to February 2020 (approx. 26 months)
Objective Response Rate (ORR)
ORR is defined as the proportion of all treated participants whose BOR is either CR or PR. BOR was determined by investigators for the reported data. Estimate of ORR and corresponding 2-sided exact 95% CI using the Clopper-Pearson method
Time frame: at Weeks 8, 16 and 24
Disease Control Rate (DCR)
DCR includes complete response (CR), partial response (PR), and stable disease (SD). Estimate of DCR and corresponding 2-sided exact 95% CI using the Clopper-Pearson method
Time frame: at Weeks 8, 16 and 24
Median Duration of Response (mDOR)
DOR for a participant with a BOR of CR or PR is defined as the time between the date of first response and the date of the first objectively documented tumor progression per RECIST v1.1/PCWG3 or death, whichever occurs first. Estimate by the Kaplan-Meier method and corresponding 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation)
Time frame: at Weeks 8, 16 and 24
Median Progression-Free Survival (mPFS)
PFS for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression or death due to any cause, whichever occurs first. Estimate by the Kaplan-Meier method and corresponding 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation) for the median and Greenwood formula for the rate.
Time frame: at Weeks 8, 16 and 24, to progression
Progression-Free Survival Rate (PFSR)
PFS for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression or death due to any cause, whichever occurs first. Estimate by the Kaplan-Meier method and corresponding 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation) for the median and Greenwood formula for the rate.
Time frame: at Weeks 8, 16 and 24
Cmax
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Cmax is defined as the maximum observed blood concentration.
Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
Tmax
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Tmax is defined as the time of maximum observed blood concentration.
Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
AUC(0-T)
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. AUC(0-T) is the area under the blood concentration-time curve from time zero to time of last quantifiable concentration.
Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
AUC(INF)
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. AUC(INF) is the area under the blood concentration-time curve from time zero extrapolated to infinite time.
Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
T-HALF
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. T-HALF is defined as the apparent terminal half-life.
Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
CLT
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. CLT is defined as the total body clearance.
Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
Vss
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Vss is defined as the volume of distribution at steady-state.
Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
Vz
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Vz is defined as the volume of distribution of the elimination phase.
Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
AUC(0-48)
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. AUC(0-T) is the area under the blood concentration-time curve from time zero to 48 hours postdose
Time frame: Cycle 1 (from time zero to 48 hours postdose)
AUC(0-8)
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. AUC(0-T) is the area under the blood concentration-time curve from time zero to 8 hours postdose
Time frame: Cycle 1 (from time zero to 8 hours postdose)
C48
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. C48 is defined as the blood concentration at 48 hours postdose.
Time frame: Cycle 1 at 48 hours postdose
Css-avg
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Css-avg is defined as the average blood concentration over a dosing interval at steady state (AUC\[0-48\]/48).
Time frame: Cycle 1 (from time zero to 48 hours postdose)
AI_AUC
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. AUC accumulation index; ratio of AUC(0-48) on Cycle 1 Day 19 to AUC(0-48) on Cycle 1 Day 15 for monotherapy.
Time frame: Cycle 1 (Day 19, Day 15)
AI_Cmax
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Cmax accumulation index; ratio of Cmax on Cycle 1 Day 19 to Cmax on Cycle 1 Day 15 for monotherapy.
Time frame: Cycle 1 (Day 19, Day 15)
T-HALFeff
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. T-HALFeff is defined as effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (exposure measure includes AUC, Cmax)
Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
Ctrough
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Ctrough is defined as the trough observed blood concentration.
Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
Number of Participants With a Positive Antibody-Drug-Antibody (ADA) Response
Baseline ADA-positive participant is defined as a participant who has an ADA-detected sample at baseline. ADA-positive participant is a participant with at least 1 ADA-positive sample relative to baseline after initiation of the treatment. Frequency distribution of baseline ADA-positive participants and ADA-positive participants after initiation of the treatment
Time frame: Cycle 1 (Day 1 pre-dose through Day 29, 240 hour), Cycle 2 (Day 1 pre-dose through Day 22, 408 hour); through Follow-up visits
| Milestone | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| Started | 4 | 3 | 3 |
| Completed | 1 | 0 | 1 |
| Not completed | 3 | 3 | 2 |
| Withdrew: Progressive disease | 2 | 3 | 1 |
| Withdrew: Study drug toxicity | 0 | 0 | 1 |
| Withdrew: Death | 1 | 0 | 0 |
Number of participants who experienced an AE during the course of the study.
| Number of Participants | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| Number of Participants With an Adverse Event (AE) | NA | NA | NA |
Number of participants who experienced a SAE during the course of the study.
| Number of Participants | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| Number of Participants With a Serious Adverse Event (SAE) | NA | NA | NA |
Number of participants who experienced an AE meeting protocol-defined DLT criteria during the course of the study.
| Number of Participants | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| Number of Participants With an Adverse Event (AE) Meeting Protocol-defined Dose Limiting Toxicity (DLT) Criteria | NA | NA | NA |
Number of participants who experienced an AE leading to discontinuation during the course of the study.
| Number of Participants | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| Number of Participants With an Adverse Event (AE) Leading to Discontinuation | NA | NA | NA |
Number of participants who experienced an AE leading to death during the course of the study.
| Number of Participants | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| Number of Participants With an Adverse Event (AE) Leading to Death | NA | NA | NA |
Number of participants who experienced a clinical laboratory test abnormality during the course of the study.
| Number of Participants | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| Number of Participants With a Clinical Laboratory Test Abnormality | NA | NA | NA |
Number of participants who experienced a vital sign abnormality or other safety biomarkers during the course of the study.
| Number of Participants | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| Number of Participants With a Vital Sign Abnormality or Other Safety Biomarkers | NA | NA | NA |
ORR is defined as the proportion of all treated participants whose BOR is either CR or PR. BOR was determined by investigators for the reported data. Estimate of ORR and corresponding 2-sided exact 95% CI using the Clopper-Pearson method
| Percentage of Participants | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| Objective Response Rate (ORR) | NA | NA | NA |
DCR includes complete response (CR), partial response (PR), and stable disease (SD). Estimate of DCR and corresponding 2-sided exact 95% CI using the Clopper-Pearson method
| Percentage of Participants | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| Disease Control Rate (DCR) | NA | NA | NA |
DOR for a participant with a BOR of CR or PR is defined as the time between the date of first response and the date of the first objectively documented tumor progression per RECIST v1.1/PCWG3 or death, whichever occurs first. Estimate by the Kaplan-Meier method and corresponding 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation)
| Number of Participants | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| Median Duration of Response (mDOR) | NA | NA | NA |
PFS for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression or death due to any cause, whichever occurs first. Estimate by the Kaplan-Meier method and corresponding 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation) for the median and Greenwood formula for the rate.
| Number of Participants | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| Median Progression-Free Survival (mPFS) | NA | NA | NA |
PFS for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression or death due to any cause, whichever occurs first. Estimate by the Kaplan-Meier method and corresponding 2-sided 95% CI using Brookmeyer and Crowley methodology (using log-log transformation) for the median and Greenwood formula for the rate.
| Percentage of Participants | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| Progression-Free Survival Rate (PFSR) | NA | NA | NA |
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Cmax is defined as the maximum observed blood concentration.
| µg/mL | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| Cmax | NA ± NA | NA ± NA | NA ± NA |
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Tmax is defined as the time of maximum observed blood concentration.
| hour | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| Tmax | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. AUC(0-T) is the area under the blood concentration-time curve from time zero to time of last quantifiable concentration.
| µg.h/mL | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| AUC(0-T) | NA ± NA | NA ± NA | NA ± NA |
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. AUC(INF) is the area under the blood concentration-time curve from time zero extrapolated to infinite time.
| µg.h/mL | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| AUC(INF) | NA ± NA | NA ± NA | NA ± NA |
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. T-HALF is defined as the apparent terminal half-life.
| hour | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| T-HALF | NA ± NA | NA ± NA | NA ± NA |
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. CLT is defined as the total body clearance.
| liter | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| CLT | NA ± NA | NA ± NA | NA ± NA |
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Vss is defined as the volume of distribution at steady-state.
| liter | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| Vss | NA ± NA | NA ± NA | NA ± NA |
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Vz is defined as the volume of distribution of the elimination phase.
| liter | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| Vz | NA ± NA | NA ± NA | NA ± NA |
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. AUC(0-T) is the area under the blood concentration-time curve from time zero to 48 hours postdose
| µg.h/mL | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| AUC(0-48) | NA ± NA | NA ± NA | NA ± NA |
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. AUC(0-T) is the area under the blood concentration-time curve from time zero to 8 hours postdose
| µg.h/mL | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| AUC(0-8) | NA ± NA | NA ± NA | NA ± NA |
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. C48 is defined as the blood concentration at 48 hours postdose.
| µg/mL | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| C48 | NA ± NA | NA ± NA | NA ± NA |
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Css-avg is defined as the average blood concentration over a dosing interval at steady state (AUC\[0-48\]/48).
| µg/mL | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| Css-avg | NA ± NA | NA ± NA | NA ± NA |
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. AUC accumulation index; ratio of AUC(0-48) on Cycle 1 Day 19 to AUC(0-48) on Cycle 1 Day 15 for monotherapy.
| ratio AUC(0-48),C1D19 to AUC(0-48),C1D15 | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| AI_AUC | NA ± NA | NA ± NA | NA ± NA |
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Cmax accumulation index; ratio of Cmax on Cycle 1 Day 19 to Cmax on Cycle 1 Day 15 for monotherapy.
| ratio of Cmax,C1D19 to Cmax,C1D15 | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| AI_Cmax | NA ± NA | NA ± NA | NA ± NA |
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. T-HALFeff is defined as effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (exposure measure includes AUC, Cmax)
| hour | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| T-HALFeff | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Pharmacokinetics of BMS-986277 were derived from blood concentration versus time data. Ctrough is defined as the trough observed blood concentration.
| µg/mL | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| Ctrough | NA ± NA | NA ± NA | NA ± NA |
Baseline ADA-positive participant is defined as a participant who has an ADA-detected sample at baseline. ADA-positive participant is a participant with at least 1 ADA-positive sample relative to baseline after initiation of the treatment. Frequency distribution of baseline ADA-positive participants and ADA-positive participants after initiation of the treatment
| Number of participants | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| Number of Participants With a Positive Antibody-Drug-Antibody (ADA) Response | NA | NA | NA |
Collected over AEs/SAEs are collected from the first dose date until the last dose date + 100 days, assessed up to February 2020 (approx. 26 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A (Part 1) | 2/4 (50%) | 1/4 (25%) | 4/4 (100%) |
| Arm B (Part 1) | 2/3 (66.7%) | 0/3 (0%) | 3/3 (100%) |
| Arm C (Part 1) | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Event | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/4 | 0/3 | 2/3 |
| Cytokine release syndromeImmune system disorders | 0/4 | 0/3 | 1/3 |
| DehydrationMetabolism and nutrition disorders | 0/4 | 0/3 | 1/3 |
| AscitesGastrointestinal disorders | 1/4 | 0/3 | 0/3 |
| Event | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) |
|---|---|---|---|
| FatigueGeneral disorders | 2/4 | 1/3 | 3/3 |
| PyrexiaGeneral disorders | 0/4 | 0/3 | 3/3 |
| NauseaGastrointestinal disorders | 3/4 | 1/3 | 2/3 |
| VomitingGastrointestinal disorders | 1/4 | 1/3 | 2/3 |
| ChillsGeneral disorders | 1/4 | 1/3 | 2/3 |
| Influenza like illnessGeneral disorders | 0/4 | 2/3 | 0/3 |
| Back painMusculoskeletal and connective tissue disorders | 0/4 | 1/3 | 2/3 |
| HeadacheNervous system disorders | 1/4 | 2/3 | 1/3 |
| DiarrhoeaGastrointestinal disorders | 2/4 | 0/3 | 0/3 |
| Decreased appetiteMetabolism and nutrition disorders | 2/4 | 1/3 | 0/3 |
| Age, Continuous(Years) | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) | Total |
|---|---|---|---|---|
| Mean | 61 ± 2.4 | 59 ± 10.4 | 47 ± 12.1 | 57 ± 9.9 |
| Age, Customized(Participants) | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) | Total |
|---|---|---|---|---|
| > 65 years | 0 | 1 | 0 | 1 |
| <= 65 years | 4 | 2 | 3 | 9 |
| Sex: Female, Male(Participants) | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) | Total |
|---|---|---|---|---|
| Female | 2 | 1 | 2 | 5 |
| Male | 2 | 2 | 1 | 5 |
| Ethnicity (NIH/OMB)(Participants) | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 1 | 0 | 1 | 2 |
| Unknown or Not Reported | 3 | 3 | 2 | 8 |
| Race (NIH/OMB)(Participants) | Arm A (Part 1) | Arm B (Part 1) | Arm C (Part 1) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 4 | 3 | 3 | 10 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2017 to primary completion in Nov 2019, 23 months.
Results were first posted in Dec 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.